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Aim: Genetic inborn along with acquired diseases arise due to the lesions in genome of multipotent hematopoietic stem cells. The aim 
was to study an influence of constitutional anomaly, Klinefelter syndrome, and additional structural rearrangements on the BCR-ABL 
tyrosine kinase inhibitor targeted therapy efficacy. Material and Methods: We describe a 32-year-old male patient with chronic myeloid 
leukemia (CML) who was detected to have sex chromosomal abnormality during evaluation for Philadelphia chromosome. Results: 
At diagnosis of CML, two clones were detected by standard cytogenetic investigation of bone marrow cells: 1) clone with translocation 
t(9;22)(q34;q11), with two sex X chromosomes and absence sex chromosome Y; 2) clone with t(9;22) and unbalanced t(Y;20)(q11;q13). 
Analysis of blast transformed lymphocytes from peripheral blood showed karyotype 47,XXY. Monitoring of targeted therapy with 
second generation inhibitor of BCR-ABL tyrosine kinase indicated a cytogenetic remission and absence of BCR-ABL1 fusion signals 
after 11 months. Conclusions: Absence of translocation t(9;22)(q34;q11) in blast transformed T-lymphocytes at diagnosis of CML 
evidences that this translocation may appear not only at the level of multipotent haemopoietic cell progenitors but also may have oligo 
lineage myeloid origin. Presence of additional structural chromosomal abnormality in the clone with t(9;22)(q34;q11) does not affect 
the efficacy of therapy with the use of second generation BCR-ABL tyrosine kinase inhibitor.
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Chronic myeloid leukemia (CML) is an acquired 
disease that arises due to the lesions in genome of mul-
tipotent hematopoietic stem cell, and makes up approxi-
mately 14% of all types of leukemias. CML is a disease 
of middle age with manifestation peak in 40–50 years old. 
The cause of the disease is not currently established, but 
in the history of some patients the chemotherapy and 
radiation have been registered [1, 2]. CML cytogenetic 
feature is the translocation t(9;22)(q34;q11) with the 
breakpoints in chromosome 9 in the band q34 (ABL 
gene) and chromosome 22 in the band q11 (BCR gene). 
The latter was designated the Philadelphia chromosome 
(Ph՛-chromosome) [3]. As a result of this translocation, 
two chimeric genes are formed: ABL1-BCR on chromo-
some 9 and BCR-ABL1 on chromosome 22. Considering 
that the anomaly occurs at an early precursor of hemato-
poietic and lymphoid tissues, it is believed that this rear-
rangement might be registered in all bone marrow (BM) 
cells, including the peripheral blood (PB) T-lymphocytes 
stimulated by phytohemagglutinin (PHA) [4]. Other 
authors indicate lack of translocation t(9;22)(q34;q11) 
in T-lymphocytes [5].
The use of inhibitors of BCR-ABL tyrosine kinase 
allows achieving both the clinical and hematologic, 
and also long-term cytogenetic and molecular genetic 
remission. This also concerns to the cases of variant 
translocations t(9;22) and additional abnormalities in the 
clone with t(9;22) in BM cells at diagnosis of CML [2, 6].
To confirm the genetic remission following the 
therapy with inhibitors of BCR-ABL tyrosine kinase, 
cytogenetic and molecular genetic control is always 
required. Achievement of the cytogenetic remission 
in 3 months of treatment with first generation BCR-ABL 
tyrosine kinase inhibitors as well as molecular genetic 
remission (one abnormal cell in 105 of BM cells) during 
the twelve months therapy, are considered as the gold 
standard of effective CML therapy [7].
Klinefelter syndrome (KS) is the most abundant anom-
aly of sex chromosomes in men occuring in 1:500 cas-
es [8]. The classic form of KS is described as 47,XXY. How-
ever, sometimes the increase in sex chromosome X num-
ber up to four copies and sex chromosome Y up to two 
copies, or mosaic form 47,XXY/46,XY appearance are 
reported [9]. The cases of CML registered in patients 
with KS are quite rare [10–14]. Among these cases, 
two patients are described in whom the effectiveness 
of BCR-ABL tyrosine kinase inhibitors-based therapy 
was assessed. In one of these cases, the patient remained 
in complete hematological and major molecular remission 
after 2 years of the therapy with first generation tyrosine 
kinase inhibitor [13], while in the other case no response 
to the same inhibitor was achieved and persistent mo-
lecular genetic alterations were documented during the 
therapy with the II generation inhibitor [15].
We, therefore, aimed to study an influence of the 
constitutional anomaly, KS, and additional structural 
rearrangements on the BCR-ABL tyrosine kinase in-
hibitor targeted therapy efficacy.
MATERIALS AND METHODS
The patient D., 32-year-old male, was referred to he-
matologist for the first time in October 2013 complaining 
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of the expressed weakness, skin pallor and weight loss 
during the year (height 175 cm, weight 104 kg). The 
patient gave written informed consent for the publica-
tion of his data analyses. Primary observation showed 
that the patient had narrow shoulders and wide hip. The 
PB contained 126.5•109/l leukocytes and 39.0 g/l hemo-
globin. Spleen size measured by ultrasound investigation 
of peritoneum was 60×120 mm. To diagnose the patient, 
the sternum puncture has been done along with the 
BM morphological evaluation and further cytogenetic 
investigation for confirmation of the probable CML diag-
nosis. BM and PB cell counts are presented in the Table.
Table. BM and PB cells indexes
BM PB
Blast cells, 6.0% Myelocytes, 23%
Leukocyte-erythrocyte ratio 21:1 Metamyelocytes, 20%
Neutrophil maturity index 1.0 Immature granulocytes, 15%
Neutrophilic granulocytes, 34%
Lymphocytes, 8%
For cytogenetic study of BM cells, the slides of meta-
phase chromosomes were prepared according to the 
conventional method followed by GTG staining. Consid-
ering that besides classic translocation t(9;22)(q34;q11) 
typical for CML, mosaics of sex chromosomes was de-
tected in patient, both the molecular genetic assay (FISH) 
on BM cells and karyotyping of PB blast transformed cells 
were performed. To define the nature of additional sex 
chromosome X, the conventional cytogenetics of blast 
transformed lymphocytes was carried out after 72 h cul-
tivation of PB and addition of PHA in the medium. Slides 
were stained by GTG-method. Presence of clonal chro-
mosomal abnormalities was described according to ISCN 
2013, when two or more metaphase plates had identical 
structural or additional (trisomy) chromosome abnormali-
ties and also in appearance of three or more metaphase 
plates with identical chromosomes monosomies [16]. 
The presence of translocation t(9;22)(q34;q11) during 
the targeted therapy was revealed by conventional cyto-
genetics and after fluorescence staining per se (on slide) 
in interphase nuclei (i-FISH). i-FISH assay was carried out 
on interphase cell nuclei after 24 h cultivation. The probe 
set Vysis LSI BCR/ABL Dual Color, Dual Fusion Transloca-
tion Probe (Abbott, USA) was used.
RESULTS AND DISCUSSION
Standard cytogenetic study on BM suspension 
cells revealed mosaic karyotype consisting of three 
clones: 46,XX,-Y,t(9;22)(q34;q11) [15]/ 46,XX,t(Y;20)
(q11;q13),t(9;22)(q34;q11),-der(Y)t(Y;20)(q11;q13)
[3]/4n± [2]. The first clone with two sex X chromosomes, 
absence of sex Y chromosome and translocation t(9;22)
(q34;q11) was detected in 15 metaphase plates (Fig. 1). 
The second clone with two sex X chromosomes, unba-
lanced structural rearrangement, namely translocation 
between chromosomes Y and 20 and loss of derivative 
chromosome due to translocation between chromosomes 
Y and 20 was detected in three metaphase plates (Fig. 2), 
and the third clone (near tetraploid) was detected in two 
metaphase plates. The results allowed us to suspect 
that the patient might have innate genetic disease, the 
KS. Moreover, it is known that during formation of abnor-
mal karyotypes the losses of sex chromosomes could 
occur. Therefore, cytogenetic study on blast transformed 
PB lymphocytes was carried out to confirm the constitu-
tional nature of additional sex chromosome X. The study 
showed karyotype 47,XXY in 20 analyzed metaphase 
plates (Fig. 3). That was confirmed by cytogenetics 
as KS. The results suggest the involvement of sex chro-
mosome Y in the formation of two abnormal clones with 
translocation t(9;22). In the first clone with a translocation 
t(9;22), a loss of sex chromosome Y was observed; in the 
second clone with a translocation t(9;22), the unbalanced 
translocation was registered involving sex chromosome 
Y and chromosome 20 with the loss of derivative chromo-
some Y, which was formed as a result of this translocation. 
The episode of the formation of different clones in BM cells 
karyotype at CML diagnosis in patient with the KS is re-
ported for the first time. The absence of t(9;22) in PHA 
blast transformed PB T-lymphocytes at diagnosis of CML 
has questioned the previous statement that this translo-
cation can be detected in lymphocytes. Perhaps in some 
cases the translocation could occur not only at the level 
of multipotent hematopoietic progenitor cell but also may 
have oligo lineage myeloid origin.
Fig. 1. Cytogenetic analysis of BM cells shows a clone with two sex 
chromosomes X and balanced translocation t(9;22)(q34;q11)
Fig. 2. Cytogenetic analysis of BM cells shows a clone with one 
sex chromosome X, balanced translocation t(9;22)(q34;q11) and 
unbalanced translocation t(Y;20)(q11;q13)
Since November 2013, the patient was schedu led 
to hydroxyurea chemotherapy at a dose of 4000 mg/day; 
there was a reduction in the leucocyte count to normal 
value while anemia remained.
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Fig. 3. Conventional cytogenetics shows karyotype 47,XXY 
in blast transformed T-lymphocytes of PB
Since December 2014, the therapy with the II gen-
eration inhibitor of BCR-ABL tyrosine kinase at a dose 
of 600 mg/day has been prescribed, which is still con-
tinued. As a result of the treatment, the patient recovered 
to normal PB and myelogram parameters, spleen size 
reduced to 100/60 mm on ultrasound examination, and 
significant increase in weight (125 kg) was observed. 
Cytogenetic and molecular cytogenetic monitoring of the 
therapy effectiveness was conducted in 11 months. 
Analysis of metaphase chromosomes in BM cells has 
revealed the karyotype containing additional sex chro-
mosome X: 47,XXY (in 20 metaphase plates). Simulta-
neously, iFISH assay was carried out on 200 interphase 
BM nuclei, and registered an absence of fusion signals 
of BCR-ABL1 and ABL1-BCR formed due to t(9;22) 
(Fig. 4).
Fig. 4. Molecular cytogenetic study shows normal distribution 
of BCR and ABL1 signals
Thus, in patient with CML in the presence of consti-
tutional chromosomal abnormality, KS, two indepen-
dent clones were recorded in BM cells at diagnosis: 
translocation t(9;22) in clone with two sex chromo-
somes X and without sex chromosome Y, and translo-
cation t(9;22) and unbalanced structural rearrange-
ment involving sex chromosome Y. The molecular cy-
togenetic remission was achieved following 11 months 
of the treatment with second generation inhibitor 
of BCR-ABL tyrosine kinase. Absence of translocation 
t(9;22)(q34;q11) in blast transformed T-lymphocytes 
may indicate that not all hematopoietic cells carry this 
abnormality. The data would be important to assess the 
effectiveness of targeted therapy for patients with the 
KS in the presence of additional structural abnormali-
ties in clone with translocation t(9;22).
ACKNOWLEDgEMENTS
We thank Prof. Danylo Gluzman, RE Kavetsky 
IEPOR of the NAS of Ukraine, for the confirmation 
of the diagnosis and disease stage. We are grateful 
to Dr. Olena Alkhimova for the valuable advice and 
assistance.
REFERENCES
1. D’Antonio J. Chronic myelogenous leukemia. Clin 
J Oncol Nurs 2005; 9: 535–53.
2. Hochhsus A, Lahaye T, Kreil S, et al. Imatinib (STI571) 
for the treatment of chronic myeloid leukemia (CML). 
In: Acute leukemia IX. W. Hiddemannet et al., eds. Springer-
Verlag Berlin Heidelberg, 2003: 109–16.
3. http://atlasgeneticsoncology.org.
4. Haferlach N, Winkemann M, Nickenig C, et al. Which 
compartments are involved in Philadelphia-chromosome 
positive chronic myeloid leukaemia? An answer at the single 
cell level by combining May-Grünwald-Giemsa staining and 
fluorescence in situ hybridization techniques. Br J Haematol 
1997; 97: 99–106.
5. Bosch GJ, Joosten AM, Kessler JH, et al. Recognition 
of BCR-ABL positive leukemic blasts by human CD4+ T cells 
elicited by primary in vitro immunization with a BCR-ABL 
breakpoint peptide. Blood 1996; 88: 3522–7.
6. Talpaz MO, O’Brein S, Jones D, et al. Molecular responses 
in patients with chronic myeloid leukemia in chronic phase treated 
with imatinib mesylate. Clin Cancer Res 2005; 11: 3425–32.
7. European LeukemiaNet (http://www.leukemia-net.org).
8. Toubai T, Tanaka J, Ota S, et al. Allogeneic bone mar-
row transplantation from an unrelated donor for the treat ment 
of chronic myelogenous leukemia in blast crisis in a patient with 
Klinefelter’s syndrome. Leuk Lymphoma 2004; 45: 829–31.
9. Smyth CM, Bremner WJ. Klinefelter syndrome. Arch 
Intern Med 1998; 158: 1309–14.
10. Eberl MM, Baer MR, Mahoney MC, et al. Unsuspect-
ed Klinefelter syndrome diagnosed during oncologic evalua-
tion: a case series. J Am Board Fam Pract 2005; 18: 132–9.
11. Oguma N, Takemoto M, Oda K, et al. Chronic myelo-
genous leukemia and Klinefelter’s syndrome. Eur J Haematol 
1989; 42: 207–8.
12. Adhvaryu SG, Jani KH, Balar DB, Shah PM. Kline-
felter syndrome patient with chronic myelogenous leukemia. 
Cancer Genet Cytogenet 1990; 48: 135–7.
13. Chennuri V, Kashyap R, Tamhankar P, Phadke S. 
Chronic myeloid leukemia in case of Klinefelter syndrome. 
Indian J Hum Genet 2014; 20: 69–71.
14. Chakraborty R, Mukkamalla SKR, Singam K, Calde-
ron N. Persistent suboptimal molecular response in a patient 
with chronic myelogenous leukemia and Klinefelter syndrome. 
Korean J Intern Med 2014; 29: 827–9.
15. Czepulkowski BH, Bhatt R, Rooney DE. Basic tech-
niques for the preparation and analysis of chromosomes 
from bone marrow and leukaemic blood. In: DE Rooney, 
BH Czepulkowski, eds. Human Cytogenetics. Malignancy and 
acquired abnormalities: a practical approach. Oxford NewYork 
Tokyo: Oxford University Press, 1992. 25 p.
16. International system for human cytogenetic 
nomenclature. LG Shaffer, J Mc Gowan-Jordan, M Schmid, 
eds. Recommendations of the International Standing Committee 
on Нuman Cytogenetic Nomenclature. Basel: S Karger, 2013. 140 p.
Copyright © Experimental Oncology, 2016
